Vesalius Biocapital Closes €120M Life Sciences-Focused Fund
Venture capital firm Vesalius Biocapital III Partners said Tuesday it closed its latest fund with €120 million ($136.6 million) in commitments that will be used to continue the firm's strategy of...To view the full article, register now.
Already a subscriber? Click here to view full article